KURA - Kura Oncology stock rises 7% as Cantor Fitzgerald begins coverage with Overweight rating
- Kura Oncology ( NASDAQ: KURA ) stock rises about 7% after Cantor Fitzgerald analyst Li Watsek initiated coverage with an Overweight rating and a price target of $30.
- The blockbuster potential of tipi combinations, and the potential of the next-generation FTI, KO-2806, is dismissed by the Street, Watsek said in his note.
- The Street has overlooked the combination opportunities of tipifarnib, a farnesyl transferase inhibitor, to address resistance in solid tumors, Watsek added in his note.
- Wall Street analysts on average rated KURA Strong Buy, with an average price target of $35.88.
For further details see:
Kura Oncology stock rises 7% as Cantor Fitzgerald begins coverage with Overweight rating